Abstracts Archive

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive lymphomas. Primary nodal subtypes: PTCL-not otherwise specified, angioimmunoblastic TCL (AITL), and anaplastic large cell lymphoma. WHO classification of lymphoid neoplasms now groups AITL, PTCL-NOS with TFH phenotype, a...

Background:Cutaneous T-cell lymphoma (CTCL) is a rare, incurable non-Hodgkin lymphoma characterized by immune dysregulation and chronic skin inflammation. Interferon-α has demonstrated activity in CTCL with response rates of 30–80%, but its use is limited by short half-life, frequent dosing, and ...

Background: Follicular helper T-cell cell lymphomas (TFHL) may exhibit complex clonal evolution.Case Presentation: A 48-year-old woman was diagnosed in 2012 with a TFHL, angioimmunoblastic-type. The disease course was indolent, with spontaneous remissions, allowing a watch-and-wait approach. Between...

A 64-year-old woman presented with fatigue, cyclic fevers, unintentional weight loss, and bilateral axillary lymphadenopathy on routine mammogram. One year earlier, she was hospitalized for fever of unknown origin and found to have bilateral axillary lymphadenopathy and pleural effusions. EBV IgG wa...

BackgroundAnti–PD-1 immunotherapy has demonstrated significant anti-tumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), achieving an objective response rate (ORR) of approximately 40% to 60% for single-agent therapy, but resistance remains a substantial challenge. Patients and...

Background: Large granular lymphocyte leukemia (LGLL) is a chronic lymphoproliferative disorder characterized by clonal expansion of abnormal cytotoxic T cells or NK cells. While STAT3 mutations occur in 50% of patients, the transcriptional programs driving disease pathogenesis remain incomplet...

Introduction:HSTCL is a rare, aggressive extranodal lymphoma which primarily affects adolescents and young adults. A substantial subset occurs in immunosuppressed patients. Objectives:Given the scarcity of large-scale data, we performed a pooled analysis to define clinical features, outcomes, a...

A 65-year-old man presented in November 2024 with a persistent cough but no other symptoms. Imaging revealed bilateral axillary, mediastinal, and hilar lymphadenopathy. Right axillary excisional lymph node biopsy showed a CD4⁺ T-cell lymphoproliferative disorder with TRBC1 restriction and aberrant...

Background:Functional precision medicine evaluates drug response of patient's tumor cells to help guide treatment. This is particularly useful for T-cell lymphoma (TCL), which has limited treatment options. In a recent prospective study, Quadratic Phenotypic Optimization Platform (QPOP/Optim.AITM) w...

Cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas that primarily affect the skin. Given the rarity of CTCL and the limited number of treatment options available, clear, accessible, and high-quality patient education is essential to support informed decisio...

Introduction and Objectives:Patients with advanced extranodal NK/T-cell lymphoma (ENKTL) or early-stage non-upper aero-digestive tract (NUAT) involvement face a poor prognosis and frequently develop hemophagocytic lymphohistiocytosis (HLH). This prospective, single-arm, multicenter, Phase II study a...

Introduction and Objectives: The relationship between PD-L1 expression and treatment outcomes in ENKTL remains poorly defined. This study (NCT04414163) aimed to explore PD-L1 expression and its association with clinical response to danburstotug. Methods: Patients received danburstotug (20 mg/kg...

We report the first known cases of iTCL-GI presenting with cutaneous manifestations,  which proved critical for identifying secondary disease involvement.  Case 1: A 29-year-old woman with limited cutaneous systemic sclerosis presented with chronic diarrhea,&n...

Introduction: Targeted therapies may induce anti-tumor immune activation in r/r-TCL. We evaluated serial immunologic changes in patients with r/r-TCL treated on the phase 1 RAdR trial (NCT04447027).Methods: Patients with r/r-TCL received up to 6 cycles of RAdR. Peripheral blood was collected prior...

IntroductionT-cell lymphoma patient outcome remains largely unsatisfactory. To identify active therapies, we screened 474 compounds as single agents and in combination with the pan-HDAC inhibitor belinostat in four TCL cell lines.Methods Cells were exposed to 0.5µM library compound, belin...

We assessed the overall survival (OS) impact of time-to-relapse (TTR) in R/R nodal-mature-T-cell-lymphomas (nMTCL) in multinational cohorts with validation using observational and randomized independent cohorts. Patients with 1L CR were assigned to TTR12 (< 12m) or without TTR12 based on time-to-pro...

INTRODUCTION: BV, an ADC targeting CD30, has shown activity in lymphomas with low CD30 expression. BV+CHP was effective in patients with PTCL with CD30 ≥10%.METHODS: SGN35-032 (NCT04569032) is a phase 2 study. Patients received 21-day cycles of BV 1.8mg/kg, cyclophosphamide 750mg/m2, and doxorubi...

Large granular lymphocytic leukemia (LGLL), a chronic, lymphoproliferative disorder of cytotoxic T (CD8) and natural killer (NK) cells, leads to neutropenia, recurrent infections, and anemia. No approved therapies exist; chronic immunosuppression makes long-term management challenging. DR-01 is a n...

Background: Peripheral T-cell lymphomas (PTCLs) comprise < 10% of non-Hodgkin lymphomas with pronounced genomic heterogeneity. The prognostic impact of KMT2A rearrangements in real-world Asian cohorts remains underexplored.Objectives: To define progression-free survival (PFS) and overall survival (O...

Introduction Large cell transformation (LCT) in mycosis fungoides/Sézary syndrome (MF/SS) portends poor survival, yet specific risk factors and real-world disparities in outcomes remain incompletely defined. Objective  In a large retrospective cohort of ...

Introduction: The prognosis for patients (pts) with advanced-stage Mycosis Fungoides (MF) and Sézary syndrome (SS) is poor and better treatments are needed. Methods: This is a phase 1, 3+3 dose de-escalation study of brentuximab vedotin (BV) and mogamulizumab (Moga) in relapsed/refractory (R/R...

Case Presentation: A 62-year-old previously healthy male presented with chronic odynophagia, left ear fullness, and hearing loss. Initial exam and nasal endoscopy demonstrated retracted tympani with left effusion, treated with antibiotics and oral steroids. Two months later, he develope...

Introduction:Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous hematological disorders with poor outcomes under standard therapies. In 2019, Ukraine launched a prospective national lymphoma registry to collect real-world data on subtypes to better understand clinical features, treatment ef...

Introduction: Dual TRBC1–CD3 immunohistochemistry (IHC) provides in-situ visualization of T-cell clonality and shows good concordance with molecular assays. Discordance, however, may reflect biologic or technical factors that alter or diminish antigen expression, creating staining patterns th...

IntroductionPeripheral T-cell lymphomas (PTCL) are a group of aggressive lymphomas. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase-δ/γ, with activity in PTCL. The duvelisib dosing regimen in PTCL was established in PRIMO (NCT03372057), a phase 2, open-label, single-arm study....

Introduction: R/R PTCL has poor outcomes and no uniform salvage standard. Epigenetic agent–containing regimens (Epi-Rx), used as mono- or combination therapy, are increasingly employed. Objectives/Methods: This meta-analysis was conducted to compare the efficacy of Epi-Rx against conventional...

Background: Large granular lymphocytic leukemia (LGLL) is characterized by a clonal expansion of cytotoxic CD8+ T or NK cells. The pathogenesis of LGLL is not fully understood, highlighting a need for a deeper understanding of the disease's molecular complexities. Although peripheral blood and hemat...

IntroductionAdult T-cell leukemia/lymphoma (ATLL) is an aggressive CD4⁺ T-cell malignancy linked to HTLV-1 infection, with limited therapeutic options and poor prognosis. CD70 is aberrantly expressed in ATLL and promotes immune evasion via CD27 signaling, making it a rational therapeutic target. C...

KMT2A (MLL1) encodes a histone H3K4 methyltransferase critical for epigenetic activation, but its role in mature T-cell lymphomas (PTCL) remains unclear. We re-analyzed the public dataset GSE58445 (n = 193) to define the transcriptional and clinical correlates of KMT2A expression. Probe-level data w...

 Large granular lymphocyte leukemia (LGLL) is a rare lymphoproliferative disorder characterized by clonal expansion of cytotoxic CD8⁺ T cells or NK cells. Somatic activating mutations in STAT3 occur in over 50% of patients, yet their functional consequences remain poorly understood. A major l...